Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 1999; 34:280-288
© 1999 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arai, M.
Right arrow Articles by Becker, L. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arai, M.
Right arrow Articles by Becker, L. C.

P-selectin inhibition prevents early neutrophil activation but provides only modest protection against myocardial injury in dogs with ischemia and forty-eight hours reperfusion

Masazumi Arai, MDa, Yoshihiro Masui, MDa, Pascal Goldschmidt-Clermont, MDa, Anthony DiPaula, BSa, Cynthia Siu, PhDa, Takeshi Kondo, MDa and Lewis C. Becker, MD, FACCa

a Division of Cardiology, Department of Medicine, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA



View larger version (21K):

[in a new window]
 
Figure 1 In vitro PB1.3 binding to dog platelets stimulated by thrombin receptor–activating peptide (TRAP) or platelet-activating factor (PAF). Mean channel fluorescence increased in a concentration-dependent manner, indicating cross-reactivity of PB1.3 to dog P-selectin.

 


View larger version (19K):

[in a new window]
 
Figure 2 Relation between infarct size and the severity of ischemia in control (open circles) and PB1.3 antibody (closed circles) groups. The regression line for PB1.3 was shifted significantly downward (p = 0.003 by analysis of covariance).

 


View larger version (22K):

[in a new window]
 
Figure 3 Time course of CD18 expression on circulating polymorphonuclear neutrophils (PMNs). In the control group, CD18 expression increased significantly at 30 min after reperfusion, and returned to the baseline level by 2 h. However, treatment with PB1.3 prevented up-regulation of CD18 at 30 min after reperfusion. The curves were also significantly different after 1 h reperfusion by profile analysis.

 


View larger version (20K):

[in a new window]
 
Figure 4 CD18 expression on circulating neutrophils at 30 min after reperfusion was correlated with the size of the area at risk in the control group (open circles, y = 58.8 + 1.6x, r = 0.83) but not in the group receiving PB1.3 (closed circles, y = 86.9 + 0.3x, r = 0.18). This suggests that the amount of neutrophil activation is dependent on the amount of ischemic–reperfused myocardium and that this activation can be prevented by PB1.3. LV = left ventricle.

 


View larger version (25K):

[in a new window]
 
Figure 5 Regional myocardial function assessed by left ventriculography. Chord shortening was averaged in the anterior (infarct) and posterior (control) regions. Wall motion was markedly reduced in the infarct region during occlusion and recovered slightly after reperfusion (**p < 0.01 vs. baseline). However, there was no significant difference in regional wall motion between the two groups at any time point.

 




 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement